Correlation Study between Genetic Polymorphisms and Blood Concentrations of Sodium Valproate in Pediatric Epilepsy Patients
Abstract
Objective: To explore the correlation between genetic polymorphisms and blood concentrations of sodium valproate in pediatric epilepsy patients, providing evidence for individualized treatment of epilepsy patients. Methods: Pediatric epilepsy patients diagnosed with epilepsy and treated with sodium valproate monotherapy in the outpatient and inpatient departments of a tertiary hospital from January 2020 to December 2023 were selected. The steady-state blood concentrations of sodium valproate were monitored, and polymerase chain reaction (PCR) was used to genotype ABCB1G2677T/A and UGT1A6T19G genes. Data were analyzed using SPSS 17.0 statistical software. Results: The UGT1A6T19G gene polymorphism significantly affected the blood concentrations of sodium valproate in epilepsy patients. Carriers of the G allele had significantly lower blood concentrations of sodium valproate than wild-type homozygotes (TT) patients, and the decrease in blood concentrations of sodium valproate was particularly significant in homozygous mutant GG genotype patients. The ABCB1G2677T/ A gene polymorphism had no statistically significant effect on the blood concentrations of sodium valproate in pediatric epilepsy patients. Conclusion: Through the study of the correlation between genetic polymorphisms and blood concentrations of sodium valproate, factors in_x0002_fluencing the steady-state trough concentrations of valproate can be revealed from a genetic perspective, providing theoretical evidence for the precise use of sodium valproate in pediatric epilepsy patients.
References
[1] Zhou X., Tan L.J., Zhao H.Y., et al. (2020) Research progress on valproic acid pharmacogenomics. Journal of Pharmaceutical Prac_x0002_tice and Service, 01, 4-17.
[2] Han H.Y., Xu M.J., Ji L.H. (2021) The impact of UGT1A6(T19G) gene polymorphism on the blood concentration of sodium valproate used for neurosurgery prevention. Chinese Journal of Drug Abuse Prevention and Treatmen, 05, 788-791.
[3] Li W.J., Peng G.L., Cai S.Y. (2019) The effect of Ugt1A6 gene polymorphism on blood concentration of sodium valproate in children with epilepsy. Chinese Journal of Clinical Rational Drug Use, 08, 152-153.
[4] Dong Y., Sun T.T., Song P.G. (2023) The effect of multidrug resistance gene 1 (MDR1) gene polymorphism on blood concentration
of sodium valproate in the treatment of elderly epilepsy. Geriatrics & Health Care, 03, 534-537.
[5] Duan K.K., Duo D.L., Zhao N., et al. (2022) Effect of UGT1A6 gene polymorphism on the blood concentration of sodium valproate in patients with neurosurgical cranial diseases. Journal of Hubei Minzu University(Medical Edition), 03, 19-22.
[6] Hu Y., Yang H., Yu M. (2024) Study on the correlation between CYP2C19 gene polymorphism and blood concentration and efficacy of sodium valproate in patients with epilepsy. Hainan Medical Journal, 04, 476-480.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
